STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: STAT
STAT+: Merck suffers a setback in Europe over its new Keytruda formulationWorldPing
Image via STAT.

What happened

In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.

Key facts

  • Reported by STAT and published Wed, 07 Oct 2026 14:06:29 UTC.

Why it matters

Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.

What to watch next

  • Case numbers and official guidance updates
  • Regulatory decisions in other countries
  • Supply, recall or access changes

Sources

The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at STAT

Follow the story

Living hubs that keep updating as this story develops.

Related WorldPing coverage